The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).
Wolfgang Wick
Consultant or Advisory Role - Lilly (U); MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; Lilly; MSD; Roche
Olivier L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Roche; Schering-Plough
Warren P. Mason
Consultant or Advisory Role - Roche
Roger Henriksson
Consultant or Advisory Role - Roche
Frank Saran
Consultant or Advisory Role - Roche
Ryo Nishikawa
Consultant or Advisory Role - Roche
Cedric Revil
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Research Funding - Roche/Genentech
Yannick Kerloeguen
Employment or Leadership Position - Roche/Genentech
Timothy Francis Cloughesy
Consultant or Advisory Role - Apogenix; Celgene; Genentech; Merck; Merck Serono; NewGen Therapeutics; Roche; Tocagen